Value through Innovation23 November 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

21.05.2014

ATS 2014
COPD: First Phase III data show lung function benefits of tiotropium + olodaterol fixed-dose combination go beyond tiotropium (Spiriva®) alone

- For media outside UK, U.S. and Canada
19.05.2014

Additional results from post-hoc analysis underline effectiveness of SPIRIVA®

- For ex-US and ex-UK Media Use Only  
18.05.2014

IPF Phase III results published in NEJM show nintedanib* slows disease progression

- For non-US health media only
15.05.2014

As the benefits and safety of Pradaxa® (dabigatran etexilate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa® to help more patients

- For media outside of the U.S., the UK & Canada only
15.05.2014

New analysis shows Boehringer Ingelheim’s Giotrif® (afatinib) is the first treatment to demonstrate significant overall survival benefit for patients with a specific type of lung cancer

- For Ex-US and Ex-UK Media Only
12.05.2014

Boehringer Ingelheim will make detailed clinical trial data available to the scientific community

07.05.2014

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

- For media outside of the U.S., the UK & Canada only
07.05.2014

New registry data highlight substantial global differences in stroke prevention for patients with an irregular heart beat

- For media outside of the U.S., the UK & Canada only
06.05.2014

Type 2 Diabetes Research: Connexios Life Sciences and Boehringer Ingelheim Enter Agreement for Novel AMPK Activators

30.04.2014

Boehringer Ingelheim Animal Health announces the 2014 European PRRS Research Award

30.04.2014

Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

- For media outside UK, U.S. and Canada
25.04.2014

Positive CHMP opinion for Pradaxa® in treatment of deep vein thrombosis and pulmonary embolism and prevention of repeat blood clots

- For media outside of the U.S., the UK & Canada only
24.04.2014

Hydra Biosciences and Boehringer Ingelheim announce worldwide collaboration to develop small-molecule inhibitors for the treatment of central nervous system diseases and disorders

17.04.2014

Volasertib, Boehringer Ingelheim´s investigational treatment of acute myeloid leukaemia, is granted ‘orphan drug designation’ in the EU and the US

- For media outside of the US only
16.04.2014

Boehringer Ingelheim receives “Facility of the Year Award” for Equipment Innovation in biopharmaceutical manufacturing

15.04.2014

Boehringer Ingelheim pleased with 2013 financial year

09.04.2014

Boehringer Ingelheim Animal Health supports PCV2 research projects with 500,000 euro

08.04.2014

FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

- For media outside of the U.S., the UK & Canada only